



### **33. TERBUTALINE (JURISDICTIONAL OPTION ONLY WHEN APPROVED BY STATE EMS MEDICAL DIRECTOR – NEW '20)**

**a) Pharmacology**

- (1) Stimulates beta-2 receptors located in the smooth bronchioles
- (2) Causes relaxation of bronchospasm

**b) Pharmacokinetics**

Relieves bronchospasm in acute and chronic airway disease with minimal cardiovascular effect

**c) Indications**

- (1) Asthma
- (2) Reversible airway obstruction associated with bronchitis or emphysema

**d) Contraindications**

- (1) Patients under 12 years of age

**e) Adverse Effects**

- (1) Tachycardia
- (2) Palpitations
- (3) Nervousness
- (4) Tremors
- (5) Dizziness
- (6) Nausea
- (7) Vomiting

**f) Precautions**

- (1) Exercise caution when administering to patients with hypertension or cardiac history
- (2) Monitor EKG

**g) Dosage**

- (1) Patients 12 years of age and older:  
Administer 0.25 mg IM. May repeat one time after 15 minutes if there is not adequate improvement. Maximum total dose 0.5 mg IM.
- (2) Patients less than 12 years of age: Not indicated